Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    ANBL1221
Show Display Options
Rank Status Study
1 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Drug: Temozolomide;   Drug: Irinotecan Hydrochloride;   Drug: Temsirolimus;   Biological: Monoclonal Antibody Ch14.18;   Biological: Sargramostim;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years